Keyphrases
Clamp Study
33%
Combination Treatment
33%
Fatty Acid Composition
33%
Fatty Acid Oxidation
33%
Gluconeogenic Enzymes
33%
Glucose Level
66%
Hepatic mRNA
33%
High Dose
33%
Hyperinsulinemic-euglycemic Clamp
33%
Hypolipidemic Effect
33%
Insulin Level
33%
Insulin Resistance
100%
Insulin Sensitivity
66%
Ligand-receptor Binding
33%
Lipid Uptake
33%
Lipoatrophic Diabetes
66%
Lipogenesis
33%
Lipogenic
33%
Liver
100%
Low Glucose
33%
MRNA Level
33%
Non-adipose Tissue
33%
Peroxisome Proliferator-activated Receptor
66%
Peroxisome Proliferator-activated Receptor Agonists
100%
Rosiglitazone
33%
Serum Triglycerides
33%
Steatosis
100%
Treatment Duration
33%
Triglyceride Level
33%
Triglycerides
33%
Biochemistry, Genetics and Molecular Biology
Beta Oxidation
33%
Drug Megadose
33%
Enzyme
66%
Fatty Acid Level
33%
Glucose Level
66%
Insulin Level
33%
Insulin Resistance
100%
Insulin Sensitivity
66%
Lipid
33%
Lipogenesis
33%
Messenger RNA
100%
Peroxisome Proliferator-Activated Receptor
66%
PPAR Agonist
100%
Rosiglitazone
33%
Triacylglycerol Blood Level
33%
Triglyceride
66%
Pharmacology, Toxicology and Pharmaceutical Science
Fatty Acid
66%
Hypolipemia
33%
Insulin Resistance
100%
Lipoatrophic Diabetes Mellitus
66%
Messenger RNA
100%
Peroxisome Proliferator Activated Receptor
66%
PPAR Agonist
100%
Rosiglitazone
33%
Steatosis
100%
Triacylglycerol
100%
Immunology and Microbiology
Adipose Tissue
20%
Agonist
100%
Drug Megadose
20%
Fatty Acid Level
20%
Fatty Acid Oxidation
20%
Glucose Level
40%
Insulin Level
20%
Insulin Resistance
100%
Insulin Sensitivity
40%
Lipogenesis
20%
Muscle
100%
Peroxisome
100%
Triacylglycerol Blood Level
20%